Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Depletion of serum amino
2024-06-13

Depletion of serum amino acids Currently, the only anticancer agents that directly target amino amc 7 metabolism are bacterial l-asparaginases (from Escherichia coli and Erwinia chrysanthemi), which are FDA-approved for treatment of pediatric and adult ALL. A potential complication of using bacte
-
farnesyl diphosphate synthase Aberrant lipid levels are asso
2024-06-13

Aberrant lipid levels are associated with various disorders, including vascular diseases and diabetes. Furthermore, important events support the idea that lipids, especially cholesterol and its derivatives, have a fundamental role in the physiopathology of AD. The farnesyl diphosphate synthase is r
-
While HTPCs are not immune cells they
2024-06-13

While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o
-
where is the breaking force In the following the details
2024-06-13

where is the breaking force. In the following, the details of the simulation are presented and subsequently, the results are discussed. The initial atomic structure is extracted from the crystal structure of single AF (PDB identification 3G37) which consist 12 monomers. As aforementioned 4 monomers
-
If the lack of specificity
2024-06-12

If the lack of specificity and the high pleiotropy may represent a problem in view of the potential chemotherapeutic features of autophagy-inducing agents, it glutathione s-transferase may switch into an advantage in the case of chemopreventive strategies. In fact, as non-pharmacologic interventions
-
br Crystal structure ACLY protein is a homotetramer of four
2024-06-12

Crystal structure ACLY protein is a homotetramer of four identical subunits [9]. Each polypeptide chain contains 1101 amino-acid residues [10]. The crystal structure of full-length ACLY protein is yet unresolved. However, Sun et al. recently succeeded in crystallizing chymotrypsin-truncated human
-
Another factor that is involved in the severity of EAE
2024-06-12

Another factor that is involved in the severity of EAE is apoptosis signal-regulating kinase 1 (ASK1), which is one of a growing number of mitogen-activated protein kinase (MAPK) kinase kinases identified in the upstream of the c-Jun N-terminal kinase and p38 MAPK pathways [12]. We previously report
-
Using this cheese mimicking matrix
2024-06-12

Using this cheese-mimicking matrix, we screened the antifungal activity of 44 LAB fermented milk-based products and 23 LAB isolates used as protective cultures against 4 fungal targets. The LAB were obtained from the culture collections of CIRM-BIA (Centre International de Ressources Microbienne-Bac
-
The preferential expression of ALOX
2024-06-12

The preferential expression of ALOX15B in human macrophages may explain why human genetic studies investigating the association of ALOX15 with cardiovascular disease did not show consistent results. Two rare functional polymorphisms have been characterized in the ALOX15 gene, which leads to increase
-
The relationship between AG and tau deposition in
2024-06-12

The relationship between AG and tau deposition in the presence of Aβ burden warrants more research in AD and in other primary tauopathies (not associated with accumulation of Aβ plaques). Our findings highlight the importance of measuring AG, as this relationship was not evident for total PD 0332991
-
Another possible scenario is that the same pathologic
2024-06-12

Another possible scenario is that the same pathologic process has different effects in different people. It might be that the pathway outlined in Fig. 6A is operative in some individuals, but other individuals have a factor Q (which could be genetic or environmental) that blocks the effect of A on T
-
A straightforward synthetic pathway was adopted
2024-06-12

A straightforward synthetic pathway was adopted to synthesize the target compounds as outlined in . The starting chloromethylquinazolinones (–) were synthesized from anthranilic Bromhexine HCl in two steps following reported procedures., , , The first step involves chloroacetylation of anthranilic
-
Although our data failed to reproduce the
2024-06-11

Although our data failed to reproduce the robust enhancement of LTP in the rat dentate with nicotine that was previously reported, our results with NS6740 suggest a more fundamental role for α7 receptor signaling in modulation of synaptic tone in the LTP pathway. The discovery of the cholinergic ant
-
br Material and methods br Results br Discussion Clinical
2024-06-11

Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De
-
In this scenario the receptor tyrosine kinase inhibitors TKI
2024-06-11

In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; PGefitinib i
16139 records 131/1076 page Previous Next First page 上5页 131132133134135 下5页 Last page